This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Warren, R. Q. Articles by Kennedy, R. C. Search for Related Content PubMed PubMed Citation Articles by Warren, R. Q. Articles by Kennedy, R. C.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, 07 1995, 400-403, Vol 2, No. 4
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Presence of neutralizing antibodies to heterologous human immunodeficiency virus type 1 isolates in sera of infected individuals is not predictive of rate of disease progression

RQ Warren, MT Wong, GP Melcher, SP Blatt, I Zapiola, MB Bouzas, G Muchinik, SA Anderson and RC Kennedy
Department of Virology and Immunology, Southwest Foundation for Biomedical Research, San Antonio, Texas 78228, USA.

These studies were undertaken to examine whether the presence of human immunodeficiency virus type 1 (HIV-1)-neutralizing antibodies in sera of infected individuals would alter the rate of disease progression. HIV-1-infected individuals (n = 87) were initially examined for neutralizing activity in vitro against both laboratory and tissue culture-adapted clinical heterologous HIV-1 isolates. The neutralizing activities of sera were determined by a 90% or greater reduction in HIV- 1 p24 levels in vitro. In a cross-sectional analysis of all infected individuals, we observed that sera from asymptomatic individuals neutralized a significantly greater number of heterologous HIV-1 isolates than sera from symptomatic patients. Patients who could be followed up longitudinally (n = 24) were then studied to determine the impact of neutralizing antibodies on the rate of disease progression. We observed no significant difference between the numbers of HIV-1 isolates neutralized in vitro by sera from patients who remained clinically stable and by those from patients who progressed rapidly. Our data indicated that the presence or absence of neutralizing antibodies to heterologous HIV-1 isolates was not associated with the rate of disease progression.